Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...

The company also has a follow-up FRα-targeting ADC – IMGN-151 – which is in phase 1. GlobalData has predicted that, with its first-to-market advantage, Elahere could generate $2.8 billion in ...

US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its ...

Elahere shows a 37% lower risk of tumor progression or death vs. chemotherapy, with a median PFS of 5.59 months vs. 3.98 months. Patients on Elahere have a median overall survival of 16.85 months ...

Genmab acquired the biotech for $1.8 billion last year, securing rights to a challenger to AbbVie’s Elahere. AbbVie alleges that ProfoundBio initially failed to produce a viable ADC pipeline and ...

has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug conjugate (ADC ...

Elahere, which AbbVie gained access to last year through its $10.1bn acquisition of ImmunoGen, is an antibody-drug conjugate (ADC), a relatively new class of cancer drugs that combine the selectivity ...

(RTTNews) - AbbVie (ABBV) announced that final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE or mirvetuximab ...